Lotus Pharmaceutical Co Ltd (1795) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.057x

Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) has a cash flow conversion efficiency ratio of 0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$1.35 Billion ≈ $42.51 Million USD) by net assets (NT$23.78 Billion ≈ $749.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 1795 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Lotus Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Lotus Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lotus Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lotus Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jiangsu Longda Superalloy Co. Ltd. A SHG:688231	N/A
Virgin Australia Holdings Ltd AU:VGN	-0.244x
Zoomlion Heavy Industry Science and Technology Co. Ltd F:8CZ	0.019x
Shanghai MicroPort EV MedTech Co. Ltd. A SHG:688351	N/A
ManpowerGroup Inc NYSE:MAN	-0.061x
Global Brands Manufacture Ltd TW:6191	0.059x
Apollo Micro Systems Limited NSE:APOLLO	1.232x
Qingdao Doublestar Co Ltd SHE:000599	0.002x

Annual Cash Flow Conversion Efficiency for Lotus Pharmaceutical Co Ltd (2009–2025)

The table below shows the annual cash flow conversion efficiency of Lotus Pharmaceutical Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Lotus Pharmaceutical Co Ltd (1795) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$23.78 Billion ≈ $749.20 Million	NT$7.48 Billion ≈ $235.72 Million	0.315x	+8.27%
2024-12-31	NT$21.18 Billion ≈ $667.30 Million	NT$6.15 Billion ≈ $193.91 Million	0.291x	+212.04%
2023-12-31	NT$17.33 Billion ≈ $546.10 Million	NT$1.61 Billion ≈ $50.86 Million	0.093x	-65.28%
2022-12-31	NT$13.87 Billion ≈ $436.91 Million	NT$3.72 Billion ≈ $117.18 Million	0.268x	+2380.88%
2021-12-31	NT$11.07 Billion ≈ $348.73 Million	NT$119.66 Million ≈ $3.77 Million	0.011x	-95.15%
2020-12-31	NT$8.75 Billion ≈ $275.53 Million	NT$1.95 Billion ≈ $61.39 Million	0.223x	+469.83%
2019-12-31	NT$7.74 Billion ≈ $243.97 Million	NT$302.81 Million ≈ $9.54 Million	0.039x	-62.31%
2018-12-31	NT$7.68 Billion ≈ $241.98 Million	NT$796.98 Million ≈ $25.11 Million	0.104x	+34.84%
2017-12-31	NT$7.70 Billion ≈ $242.50 Million	NT$592.29 Million ≈ $18.66 Million	0.077x	-47.82%
2016-12-31	NT$8.36 Billion ≈ $263.42 Million	NT$1.23 Billion ≈ $38.85 Million	0.147x	+19.48%
2015-12-31	NT$8.73 Billion ≈ $275.06 Million	NT$1.08 Billion ≈ $33.95 Million	0.123x	+205.33%
2014-12-31	NT$8.81 Billion ≈ $277.59 Million	NT$-1.03 Billion ≈ $-32.53 Million	-0.117x	-81.88%
2013-12-31	NT$1.49 Billion ≈ $46.87 Million	NT$-95.84 Million ≈ $-3.02 Million	-0.064x	+24.60%
2012-12-31	NT$637.28 Million ≈ $20.08 Million	NT$-54.45 Million ≈ $-1.72 Million	-0.085x	+33.24%
2011-12-31	NT$596.05 Million ≈ $18.78 Million	NT$-76.29 Million ≈ $-2.40 Million	-0.128x	-239.89%
2010-12-31	NT$646.95 Million ≈ $20.38 Million	NT$59.19 Million ≈ $1.86 Million	0.091x	-53.31%
2009-12-31	NT$456.73 Million ≈ $14.39 Million	NT$89.50 Million ≈ $2.82 Million	0.196x	--

About Lotus Pharmaceutical Co Ltd

TW:1795 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$1.58 Billion

NT$50.20 Billion TWD

Market Cap Rank

#7165 Global

#223 in Taiwan

Share Price

NT$191.00

Change (1 day)

-2.30%

52-Week Range

NT$186.00 - NT$363.00

All Time High

NT$363.00